Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 1.00 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 1.00 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16528703 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2GRM3 | |
| SCHEMBL16528808 | 1.00 | FOLH1 (1.00) | FOLH1NAALAD2GRM3 | |
| Benzene SCHEMBL8056005 | 0.96 | FOLH1 (0.92) | FOLH1NAALAD2GRM3 | |
| SCHEMBL12145031 | 0.88 | FOLH1 (1.00) | FOLH1NAALAD2GRM3 | |
| SCHEMBL4135913 | 0.87 | GRM3 (1.00) | FOLH1NAALAD2GRM3 | |
| SCHEMBL8052868 | 0.83 | FOLH1 (0.70) | FOLH1NAALAD2GRM3 | |
| SCHEMBL18309791 | 0.83 | FOLH1 (0.71) | FOLH1NAALAD2GRM3 | |
| SCHEMBL1374871 | 0.83 | FOLH1 (0.71) | FOLH1NAALAD2GRM3 | |
| SCHEMBL15739395 | 0.83 | FOLH1 (0.71) | FOLH1NAALAD2GRM3 | |
| SCHEMBL20529841 | 0.82 | GRM3 (0.81) | FOLH1NAALAD2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508271-B2 | Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-12-30 | — | — | US | claimed |
| US-20250269044-A1 | PSMA-TARGETED DENDRIMER NANOPLATFORM FOR CANCER DETECTION AND THERAPY | WASHINGTON STATE UNIVERSITY | 2025-08-28 | — | — | US | claimed |
| WO-2025092300-A1 | USE OF ADRENORECEPTOR AGONISTS IN PROMOTING HEMATOPOIETIC REGENERATION | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2025-05-08 | — | — | WO | claimed |
| US-20250137160-A1 | ANODIZED ENCLOSURE WITH FINGERPRINT RESISTANT SEALING TECHNOLOGY | APPLE INC. | 2025-05-01 | — | — | US | claimed |
| CN-119907204-A | Anodized shell with fingerprint resistant sealing technique | 苹果公司 | 2025-04-29 | — | — | CN | claimed |
| EP-3609544-B1 | PRODRUGS OF 2-PMPA FOR HEALTHY TISSUE PROTECTION DURING PSMA-TARGETED CANCER IMAGING OR RADIOTHERAPY | UNIV JOHNS HOPKINS (US) | 2025-04-09 | — | — | EP | claimed |
| US-20250064948-A1 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | THE JOHNS HOPKINS UNIVERSITY | 2025-02-27 | — | — | US | claimed |
| CN-110730908-B | Engineered cells expressing Prostate Specific Membrane Antigen (PSMA) or modified versions thereof and related methods | 朱诺治疗学股份有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-117138837-B | Modified halloysite composite material, halloysite-based three-phase interface catalytic membrane, and preparation methods and applications thereof | 淮安中顺环保科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-111801121-B | 2-PMPA prodrugs for healthy tissue protection during PSMA-targeted cancer imaging or radiation therapy | 约翰霍普金斯大学 | 2023-12-01 | — | — | CN | claimed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | claimed |
| CN-1230889-A | NAALADase compositions and methods for treating glutamate abnormalities and for producing neuronal activity in animals | GUILFORD PHARM INC (US) | 1999-10-06 | — | — | CN | claimed |
| WO-1999033848-B1 | PROCESS FOR PREPARING ENANTIOMER-ENRICHED HYDROXYPHOSPHINYL DERIVATIVES | GUILFORD PHARM INC (US) | 1999-08-12 | — | — | WO | claimed |
| WO-1999033849-A1 | PRODRUGS OF NAALADASE INHIBITORS | GUILDFORD PHARMACEUTICALS INC. (US) | 1999-07-08 | — | — | WO | claimed |
| WO-1999008521-A1 | TREATMENT OR PROPHYLAXIS OF RETINAL PATHOLOGY AND SPINAL CORD INJURY | DEPARTMENT OF THE ARMY, U.S. GOVERNMENT (US) | 1999-02-25 | — | — | WO | claimed |
| US-5804602-A | N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-09-08 | — | — | US | claimed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| WO-1997048399-A1 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508271-B2 | Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy | KLK3, CTSA, PTMA | FOLH1 8/4885NAALAD2 514/4885GRM3 2377/4885 |
| US-20250064948-A1 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | DGKI, PGC, MPC2 | FOLH1 149/4885NAALAD2 572/4885GRM3 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.